SYDNEY, Australia, Dec. 14 Pharmaxis(ASX: PXS; Nasdaq: PXSL) today announced the appointment of Pulmocor SA tomarket and distribute its asthma diagnostic tool, Aridol in Portugal.
"Portugal was one of the 13 European countries included in the successfulmutual recognition procedure earlier this year," said Pharmaxis ChiefExecutive Officer Dr Alan Robertson.
"Bronchial challenge testing is a common procedure in Potuguese hospitalsand we have sought a distributor that already has a strong franchise in thismarket and will provide the best support for Aridol; we are delighted toannounce our agreement with Pulmocor."
Mr Ricardo Villar, President of Pulmocor said, "Founded in 1982, Pulmocorhas a strong reputation for quality and excellence among respiratoryspecialists and brings many years of bronchial challenge testing experience tothe promotion of Aridol. Pulmocor is currently extending its activity intospecialist pharmaceutical products and Aridol represents an important additionto our portfolio and our ability to service respiratory specialists."
Aridol has already been approved in Europe by the mutual recognitionprocedure and is now awaiting confirmation of national approval in Portugal.
A simple to use airways inflammation test, Aridol is administered as a drypowder in a hand held inhaler. Doctors can use the results of this test toidentify airway hyper-responsiveness -- a hallmark of asthma.
To find out more about Pharmaxis go to http://www.pharmaxis.com.au .
To find out more about Aridol go to http://www.pharmaxis.com.au/target-diseases-and-products/our-products/our-products_home.cfm .
(Note: If the URL above wraps to a second line, paste both lines into thebrowser.)
The statements contained in this media release that are not purelyhistorical are forward-looking statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended. Forward-looking statements inthis media release include statements regarding our expectations, beliefs,hopes, goals, intentions, initiatives or strategies, including statementsregarding the potential for Aridol and/or Bronchitol. All forward-lookingstatements included in this media release are based upon information availableto us as of the date hereof, and we assume no obligation to update any suchforward-looking statement as a result of new information, future events orotherwise. We cannot guarantee that any product candidate will receive FDA orother regulatory approval or that we will seek any such approval. Factors thatcould cause or contribute to such differences include, but are not limited to,factors discussed in the "Risk Factors and Other Uncertainties" section of ourForm 20-F lodged with the U.S. Securities and Exchange Commission.CONTACT: Alan Robertson - Chief Executive Officer Tel: +61-2-9454-7200 Email: firstname.lastname@example.org Released through: United States: Brandon Lewis, Trout Group Tel: +1-646-378-2915 Email: email@example.com Australia: Felicity Moffatt Tel: +61-418-677-701 Email: firstname.lastname@example.org
SOURCE Pharmaxis Ltd